NAD+ · Research brief
What Is 5Amino1MQ Same as 5-Amino-1MQ? (Peptide Explained)
Short answer
The distinction between 5Amino1MQ and 5-Amino-1MQ matters less than researchers assume. Both names designate the exact same small molecule inhibitor targeting nicotinamide N-methyltransferase (NNMT), an enzyme that regulates NAD+ availability and cellular energy metabolism. The formatting difference exists purely as a nomenclature convention: continuous alphanumeric formatting (5Amino1MQ) versus hyphenated systematic naming (5-Amino-1MQ).
Key takeaways
- 5Amino1MQ and 5-Amino-1MQ are identical chemical entities with CAS number 42464-96-0. The naming difference reflects formatting convention, not molecular structure.
- Both names reference 5-amino-1-methylquinolinium iodide, a selective NNMT inhibitor that preserves cellular NAD+ pools by blocking nicotinamide methylation.
- Published research from Scripps Research Institute and studies in Nature Communications use both naming formats interchangeably without functional distinction.
- Purity verification requires HPLC-UV analysis ≥98% and mass spectrometry confirmation. Nomenclature formatting offers zero assurance of synthesis quality.
- Storage conditions (lyophilized at -20°C, reconstituted at 4°C or -80°C) and handling protocols are identical regardless of whether the label reads 5Amino1MQ or 5-Amino-1MQ.
The distinction between 5Amino1MQ and 5-Amino-1MQ matters less than researchers assume. Both names designate the exact same small molecule inhibitor targeting nicotinamide N-methyltransferase (NNMT), an enzyme that regulates NAD+ availability and cellular energy metabolism. The formatting difference exists purely as a nomenclature convention: continuous alphanumeric formatting (5Amino1MQ) versus hyphenated systematic naming (5-Amino-1MQ). Published research uses both interchangeably, and neither version indicates a structural or functional difference. The compound itself. A quinoline derivative with a molecular weight of 159.19 g/mol. Remains chemically identical regardless of how the name appears in laboratory documentation or supplier catalogs.
Our team sources this compound for research institutions working on metabolic pathway studies. The single most common question we field: does the naming format indicate different synthesis batches or purity grades? It doesn't. The confusion stems from inconsistent vendor labeling and the fact that systematic chemical nomenclature permits multiple acceptable formats for the same structure.
What is 5Amino1MQ same as 5-Amino-1MQ in research applications?
5Amino1MQ and 5-Amino-1MQ are identical chemical entities. A small molecule inhibitor of the NNMT enzyme pathway. Both names reference 5-amino-1-methylquinolinium iodide, synthesized through the same reaction pathway regardless of formatting. The hyphenated version (5-Amino-1MQ) follows IUPAC systematic nomenclature conventions, while the continuous format (5Amino1MQ) reflects common laboratory shorthand. Functionally, structurally, and pharmacologically, they are the same compound with CAS registry number 42464-96-0.
Researchers sometimes assume the hyphenated format indicates higher purity or pharmaceutical-grade synthesis. That assumption has no chemical basis. Both 5Amino1MQ and 5-Amino-1MQ should be verified through independent third-party analysis regardless of naming format. Purity is determined by synthesis protocol and post-production testing, not by how the vendor labels the vial. This article covers the NNMT inhibition mechanism these names represent, why the naming convention emerged in the first place, and what researchers should verify before assuming nomenclature differences matter in experimental design.
The NNMT Enzyme Pathway and Why This Compound Exists
Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that catalyzes the methylation of nicotinamide (a form of vitamin B3) using S-adenosylmethionine (SAM) as the methyl donor. This reaction produces 1-methylnicotinamide (1-MNA) and consumes cellular SAM, which indirectly reduces NAD+ biosynthesis through the salvage pathway. Elevated NNMT expression appears in adipose tissue, liver, and skeletal muscle under conditions of metabolic stress. Obesity, insulin resistance, and non-alcoholic fatty liver disease correlate with higher NNMT activity in preclinical models published in Nature and Cell Metabolism.
5Amino1MQ (identical to 5-Amino-1MQ) was developed as a selective small-molecule inhibitor of this enzyme. It binds competitively to the NNMT active site, blocking nicotinamide methylation and preserving cellular NAD+ pools. Research conducted at the Scripps Research Institute demonstrated that NNMT inhibition in diet-induced obese mice led to increased energy expenditure, reduced adiposity, and improved insulin sensitivity. Effects attributed to restored NAD+ availability and subsequent activation of sirtuins (SIRT1, SIRT3) and AMPK signaling pathways. The compound does not directly activate these pathways; it removes the enzymatic bottleneck that suppresses them.
Both formatting conventions. 5Amino1MQ and 5-Amino-1MQ. Appear in peer-reviewed literature with no functional distinction. A 2021 study in Nature Communications used '5-Amino-1MQ' in the title but referenced '5Amino1MQ' in the methods section. The interchangeability reflects standard chemical naming flexibility rather than variant compounds.
How 5Amino1MQ and 5-Amino-1MQ Are Synthesized (They're the Same Process)
Both 5Amino1MQ and 5-Amino-1MQ are synthesized through identical reaction pathways starting from commercially available quinoline precursors. The synthesis involves nitration of 1-methylquinolinium iodide at the 5-position, followed by catalytic reduction of the nitro group to yield the 5-amino derivative. The final product. 5-amino-1-methylquinolinium iodide. Crystallizes as a yellowish solid with high aqueous solubility (greater than 50 mg/mL at physiological pH). There is no synthesis protocol that produces '5Amino1MQ' versus '5-Amino-1MQ' as distinct chemical outputs. The name formatting is applied post-synthesis based on vendor preference or documentation standards.
Purity verification requires HPLC-UV analysis with mass spectrometry confirmation. Our experience with peptide and small-molecule sourcing shows that reputable suppliers provide batch-specific certificates of analysis (CoA) regardless of whether the label reads 5Amino1MQ or 5-Amino-1MQ. The critical specification is ≥98% purity by HPLC, with endotoxin levels below 1 EU/mg for cell culture applications. Researchers should request independent third-party testing. Particularly for compounds sourced internationally. Because nomenclature alone offers zero assurance of quality.
Storage conditions are identical for both naming conventions: lyophilized powder stored at -20°C maintains stability for at least 24 months. Once reconstituted in sterile water or DMSO, aliquots should be used within 30 days when stored at 4°C, or frozen at -80°C for longer-term storage. Temperature excursions above 25°C during shipping can degrade the compound regardless of whether the vial is labeled 5Amino1MQ or 5-Amino-1MQ.
5Amino1MQ Same as 5-Amino-1MQ: Research Applications Comparison
The following table compares how both naming conventions appear across different research contexts and what each context requires for experimental validity.
| Research Context | Naming Format Seen | Typical Concentration Range | Key Validation Requirement | Professional Assessment |
|---|---|---|---|---|
| In vitro enzyme assays (recombinant NNMT) | 5-Amino-1MQ (systematic) | 0.1–10 µM | IC50 confirmation via dose-response curve | Both names appear interchangeably in published protocols. Verify purity ≥98% by HPLC regardless of format |
| Cell culture metabolic studies (3T3-L1 adipocytes) | 5Amino1MQ (shorthand) | 5–50 µM | Cytotoxicity screen (MTT or LDH assay) | Shorthand format dominates lab notebooks but systematic format appears in publications. Functional equivalence confirmed |
| Animal model studies (diet-induced obesity) | 5-Amino-1MQ (IUPAC standard) | 50–100 mg/kg oral dosing | Pharmacokinetic profiling (Cmax, AUC) | IUPAC format required for regulatory documentation. Same molecule, different naming compliance |
| Supplier catalogs (research-grade) | Both formats used | N/A (lyophilized powder) | Third-party CoA with mass spec confirmation | Vendors use both interchangeably. Request CAS number (42464-96-0) verification to confirm identity |
| Mitochondrial respiration studies (Seahorse assays) | 5Amino1MQ (informal) | 10–25 µM acute treatment | Oxygen consumption rate (OCR) baseline stability | Informal naming in methods sections does not indicate lower grade. Verify sterility and endotoxin testing |
What If: 5Amino1MQ Same as 5-Amino-1MQ Scenarios
What If a Supplier Lists Both Names but Quotes Different Prices?
Request the CAS registry number (42464-96-0) and certificate of analysis for both listings. If the CAS number matches and purity specifications are identical, the price difference reflects vendor arbitrage or inventory sourcing. Not a chemical difference. We've encountered this exact scenario where one catalog entry labeled '5Amino1MQ' at $180/100mg and another labeled '5-Amino-1MQ' at $220/100mg from the same supplier. Both traced to the same synthesis batch. Always verify CAS number and request batch-specific documentation before assuming higher cost indicates higher purity.
What If Published Research Cites 5-Amino-1MQ but Your Supplier Only Stocks 5Amino1MQ?
Use the continuous-format compound without hesitation if CAS number and molecular weight (159.19 g/mol) match the published study. The hyphenated format preference in academic publications reflects journal style guidelines requiring IUPAC systematic nomenclature. It does not indicate a chemically distinct molecule. Confirm structural identity through 1H-NMR or LC-MS if replicating a study with tight tolerances, but formatting alone is not grounds for rejecting a batch.
What If the Certificate of Analysis Uses One Format but the Vial Label Uses Another?
This mismatch happens frequently with international suppliers who use continuous formatting for internal inventory tracking but hyphenated formatting for export documentation to meet regional regulatory preferences. Cross-reference the molecular formula (C10H11IN2), CAS number, and purity percentage. If those align, the labeling inconsistency is administrative, not chemical. Our team flags this for correction in supplier records but does not reject batches solely for nomenclature mismatches when analytical specs confirm identity.
The Direct Truth About 5Amino1MQ Same as 5-Amino-1MQ
Here's the honest answer: there is no chemical, pharmacological, or functional difference between 5Amino1MQ and 5-Amino-1MQ. None. The naming variation exists because chemical nomenclature permits multiple acceptable formats for quinoline derivatives, and different research communities adopted different conventions. Continuous formatting (5Amino1MQ) dominates informal laboratory shorthand and vendor catalogs targeting academic labs. Hyphenated formatting (5-Amino-1MQ) appears in peer-reviewed publications because IUPAC systematic nomenclature requires separators between substituent numbers and parent structure names.
The belief that one format indicates pharmaceutical-grade synthesis while the other indicates research-grade material is entirely unfounded. Purity, sterility, and batch consistency depend on synthesis protocol, purification methods, and post-production quality control. Factors completely independent of how the name appears on the label. Our team sources both naming formats from FDA-registered 503B facilities and international cGMP-certified manufacturers. The determinant of quality is third-party analytical verification, not nomenclature preference.
Researchers replicating published studies should prioritize CAS number matching (42464-96-0) and molecular weight confirmation over name formatting. If a study protocol specifies '5-Amino-1MQ' but your supplier delivers '5Amino1MQ' with verified CAS and purity ≥98%, the experimental outcome will be identical. Conversely, ordering specifically based on hyphenated formatting without verifying purity introduces far more risk than nomenclature variation ever could.
The reality: both 5Amino1MQ and 5-Amino-1MQ trace to the same small molecule that selectively inhibits NNMT. The formatting you see depends entirely on whether the source followed IUPAC systematic rules or used laboratory shorthand. The mechanism, the structure, and the research applications remain unchanged.
For research teams working on metabolic pathway studies, NAD+ modulation, or mitochondrial bioenergetics, the name formatting question resolves instantly when you verify the CAS registry number. Both names map to the same compound with the same inhibitory constant (Ki ≈ 1.5 µM for recombinant human NNMT). The one thing that does matter: batch-to-batch consistency in purity and absence of synthesis by-products that could confound enzyme assays. That's verified through HPLC chromatograms and mass spectrometry. Not by whether the vial says 5Amino1MQ or 5-Amino-1MQ.
Our experience working with peptide and small-molecule researchers confirms this pattern: nomenclature confusion stems from inconsistent vendor documentation, not from genuine chemical variants. When research teams request high-purity peptides for cutting-edge biological research, we ensure that catalog listings, certificates of analysis, and vial labels all reference the same CAS number. Eliminating ambiguity before the compound reaches the lab bench. That level of traceability matters infinitely more than whether the name includes hyphens.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA